title: The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study Group.
authors.affiliation: Département d'Hématologie et Oncologie Médicale, CHU La Milétrie, Poitiers, France.
authors.forename: F
authors.initials: F
authors.lastname: Guilhot
authors.forename: A
authors.initials: A
authors.lastname: Guerci
authors.forename: D
authors.initials: D
authors.lastname: Fiere
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
authors.forename: F
authors.initials: F
authors.lastname: Maloisel
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: D
authors.initials: D
authors.lastname: Guyotat
authors.forename: H
authors.initials: H
authors.lastname: Rochant
authors.forename: A
authors.initials: A
authors.lastname: Najman
authors.forename: F
authors.initials: F
authors.lastname: Nicolini
authors.forename: P
authors.initials: P
authors.lastname: Colombat
authors.forename: J F
authors.initials: JF
authors.lastname: Abgrall
authors.forename: N
authors.initials: N
authors.lastname: Ifrah
authors.forename: J
authors.initials: J
authors.lastname: Brière
authors.forename: F
authors.initials: F
authors.lastname: Bauters
authors.forename: M
authors.initials: M
authors.lastname: Navarro
authors.forename: P
authors.initials: P
authors.lastname: Morice
authors.forename: D
authors.initials: D
authors.lastname: Bordessoule
authors.forename: J P
authors.initials: JP
authors.lastname: Vilque
authors.forename: B
authors.initials: B
authors.lastname: Desablens
authors.forename: G
authors.initials: G
authors.lastname: Tertian
authors.forename: M
authors.initials: M
authors.lastname: Blanc
authors.forename: C
authors.initials: C
authors.lastname: Chastang
authors.forename: J
authors.initials: J
authors.lastname: Tanzer
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage*; D004361:Drug Tolerance; D005602:France; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000628:therapy*; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D011994:Recombinant Proteins
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D003561:Cytarabine; D006918:Hydroxyurea